Given the prevalence of HR–DDR in cutaneous melanoma and the promising role of PARP inhibition in targeting HR–DDR melanomas in preclinical models, exploring the clinical efficacy of PARP inhibition in melanoma patients with HR–DDR mutations is strongly warranted. This evidence concerns the gene PARP1 and melanoma.